## CLAIMS

1. A safety dispenser for inducing in members of a patient population an antidiuretic effect while reducing the risk that a member of the population may develop hyponatremia, the dispenser comprising:

a reservoir having disposed therein a composition comprising a desmopressin preparation, cyclopentadecanolide, cottonseed oil, Sorbitan monolaurate and polysorbate 20 ~~and a nasal membrane permeation enhancer~~ in an amount sufficient to constitute multiple drug doses, said composition ~~characterized by~~having a desmopressin bioavailability greater than 5%;

an outlet in communication with said reservoir;

a manually actuatable pump for serially dispensing from said reservoir through said outlet, and to an intranasal surface of a patient, measured doses of said composition in the form of a spray,

wherein the amount of the disposed composition is sufficient to enable respective doses of spray being restricted within the range of 0.5 ng desmopressin per kilogram of the patient's body weight and 75 ng desmopressin per kilogram of the patient's body weight so as to achieve a target $C_{max}$ in members of said patient population less than ~~15 +/- 3~~18 pg/ml of blood,

~~respective successive spray doses of the same volume being sufficient to establish in a said patient by drug transport across intranasal mucosal membranes delivery of a maximum blood concentration ($C_{max}$) of desmopressin having a coefficient of variation similar to the coefficient of variation of $C_{max}$ produced by a subcutaneous dose of desmopressin designed to achieve the same target $C_{max}$, and wherein respective successive spray doses establish in a said patient a $C_{max}$ of desmopressin in successively administered doses that vary by no more than 100%~~

wherein the dispenser delivers the composition as a multiplicity of droplets, wherein 10% of droplets are smaller than 20 µm in diameter and 90% are smaller than 300 µm in diameter.

~~2. The dispenser of claim 1 wherein respective successive spray doses establish in a said patient a $C_{max}$ of desmopressin having a coefficient of variation within 50% of the coefficient of variation of said subcutaneous dose.~~

~~3. The dispenser of claim 2 wherein respective successive spray doses establish in a said patient a $C_{max}$ of desmopressin having a coefficient of variation within 25% of the coefficient of variation of said subcutaneous dose.~~

~~4. The dispenser of claim 1 wherein respective successive spray doses establish in a said patient by intranasal delivery a $C_{max}$ of desmopressin in successively administered doses that vary by no more than 50%.~~

~~5~~2. The dispenser of claim 1 wherein respective successive spray doses ~~establish~~ enables in a said patient a $C_{max}$ of desmopressin to be within one of the following blood concentration ranges (in pg/ml of blood): 1-3, 2-5, 3-6, 4-7, 5-8, 6-9, 7-10.

~~6~~3. The dispenser of claim 1 wherein respective doses of spray ~~are restricted to achieve~~enables a target $C_{max}$ in members of said patient population less than 10 pg/ml of blood.

~~7. The dispenser of claim 1 further comprising means for blocking dispensing of a second said desmopressin dose from said reservoir for a predetermined time interval after dispensing a said dose.~~

~~8~~4. The dispenser of claim 1 ~~formulated~~ wherein the composition~~to~~ induces antidiuresis in a target patient population for less than six hours.

~~9~~5. The dispenser of claim ~~8~~ 4 wherein the composition ~~formulated to~~ induces antidiuresis in a target patient population for between 2 and 4 hours.

~~10~~6. The dispenser of claim 1 wherein the composition ~~formulated to~~ induces antidiuresis in a target patient population for between 4 and 7 hours.

~~11~~7. The dispenser claim 1 formulated for a target population selected from children, children weighing less than 35 kg, children weighing between 35 and 50 kg, adult females, adult males, females weighing between 50 and 75 kg, males weighing between 70 and 85 kg, and males weighing more than 85 kg.

~~12. The dispenser of claim 1 wherein the dose comprises a multiplicity of droplets with an average volume distribution in the range of 20 µm for D10 to 300 µm for D90.~~

~~13. The dispenser of claim 1 wherein said permeation enhancer is selected from the group consisting of macrocyclic esters, diesters, amides, diamides, amidines, diamidines, thioester, dithioester, thioamides, ketones or lactones.~~

~~14~~8. The dispenser of claim 1 wherein said composition ~~is characterized by~~has a desmopressin bioavailability greater than 10%.

~~15~~9. The dispenser of claim ~~14~~ 8 wherein said composition ~~is characterized by~~has a desmopressin bioavailability greater than 15%.

~~16~~10. The dispenser of claim ~~15~~ 9 wherein said composition ~~is characterized by~~has a desmopressin bioavailability greater than 20%.

~~17~~11. The dispenser of claim 1 being free of preservatives.

~~18. The dispenser of claim 1 wherein said pump prevents backfill of bacterially contaminated ambient air after a dispensing of said composition.~~